Documentos de Académico
Documentos de Profesional
Documentos de Cultura
William Otero Regino, MD,1 Alba Alicia Trespalacios, MSc,2 Elder Otero.3
Palabras clave
Helicobacter, triple terapia, levofloxacina, terapia secuencial, resistencia primaria.
Summary
Since when Helicobacter pylori was discovered, the eradication has been one of the most important cha- llenges in
gastroenterology. In many places, the prevalence of primary resistance of microorganism to the different antibiotics
is not known, and these are used empirically. In daily practice, no routine test is used to verify the eradication, and
therefore do not know the effectiveness of the schemes. Knowing these two factors is possible identify those still infected
and choose the next rescue therapy in a rational form. The absence of information on pre-treatment resistance is a problem
that cannot measure the impact of resistance to thera- peutic failure. A global level, the standard triple therapy has lost the
effectiveness that it had in the past and sequential therapy is not equally effective everywhere, especially in regions
where there is high resistance to clarithromycin and metronidazole. The schemes have proved effective with levofloxacin
triple therapies as first line therapy or rescue, but it is necessary that each region takes its own schemes of treatment based
on susceptibility tests and pharmacogenomic studies.
Key words
Helicobacter, triple therapy, levofloxacin, sequential therapy, primary resistance.
Helicobacter pylori (H. pylori) es uno de los principales desde el África oriental, con las cuales, este
pató- genos de la humanidad, con la cual ha mantenido microorganismo fue diseminado hacia otras regiones del
una estre- cha relación desde hace aproXimadamente mundo (1, 2). A pesar de esta convivencia desde la
58.000 años, mucho antes de que se iniciaran las prehistoria, H. pylori solo fue reconocido como
migraciones humanas patógeno hace un poco más de 25